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In 2000, annual mass administration of diethlycarba-
mazine and albendazole began in Leogane Commune,
Haiti, to interrupt transmission of lymphatic filariasis (LF).
After 5 years of treatment, microfilaremia, antigenemia, and
mosquito infection rates were significantly reduced, but LF
transmission was not interrupted. These finding have impli-
cations for other LF elimination programs.
G
lobally, more than 1 billion persons are at risk for
lymphatic filariasis (LF), a mosquito-transmitted par-
asitic infection that causes lymphedema and hydrocele.
Transmission of LF can be interrupted by annual mass
treatment with drugs that target microfilariae, the stage of
the parasite that circulates in the blood (1,2). Programs in
Egypt, Samoa, Zanzibar, and other settings have recently
completed 5 rounds of mass drug administration (MDA)
(3,4), a proposed endpoint for treatment, and are now con-
fronted with a critical question: can MDAbe stopped with-
out fear of recrudescence of LF infection?
The LF demonstration project in Leogane, Haiti, was
designed as an operational research project to monitor the
impact of MDA on LF infection in a high-prevalence set-
ting. The intervention was annual MDAwith diethylcarba-
mazine (DEC) and albendazole. We discuss how sentinel
site data were used to determine whether to continue MDA
after 5 rounds and how our experience may be relevant to
other LF programs.
Leogane is located 30 km west of Port-au-Prince.
Before the first MDA in 2000, 4 sentinel sites in Leogane
commune were selected for annual follow-up of microfi-
laremia and antigenemia (5). Monitoring of filarial infec-
tion prevalence in the vector, Culex quinquefasciatus,
began in these sites 3 months before the first MDA, using
CDC gravid traps (Model 1712, J.W. Hock Co.,
Gainesville, FL, USA) (6); testing continued on a semi-
monthly basis. Infected mosquitoes were defined as those
carrying microfilariae or larvae (L1–L3); L3 were the
infectious larval stage. Protocols for collecting data from
sentinel sites were approved by the Centers for Disease
Control and Prevention Institutional Review Board and the
Ethics Committee at Hôpital Ste. Croix.
In October 2000 and every October thereafter, DEC (6
mg/kg) and albendazole (400 mg; GlaxoSmithKline,
Brentford, UK) were co-administered at stationary posts to
persons >2 years of age, excluding pregnant women and
persons too ill to receive the drugs. Adverse events were
monitored each year by recording the number of persons
who returned to distribution posts with complaints. Cluster
surveys were conducted after the first and third MDA to
assess coverage and the effect of health messages on com-
pliance (7,8).
Reported coverage in 2000–2004 for MDAs 1–5 was
69%, 50%, 84%, 89%, and 104%, respectively (Table).
Decreased coverage in 2001 may have been related to a
relatively high incidence of adverse events caused by death
of microfilariae and adult worms during the first MDA(9).
The increase in reported coverage in 2004 may have been
due to an influx of displaced persons from areas of Haiti
affected by civil strife. Survey-based coverage in 2000 and
2002 was 71% and 79%, respectively (7,8). Adverse
events diminished with each year of treatment, from 23.1%
of persons treated during 2000 to 3% during 2004
(p<0.0001).
Baseline microfilaremia prevalence rates were 0.8%,
7%, 12%, and 16% in the sentinel sites of Mapou, Barrier-
Jeudi, Masson-Mathieu, and Leogane, respectively
(Figure 1). Microfilaremia prevalence decreased signifi-
cantly in each of the sentinel sites (Mapou, p = 0.0291;
each of the other sites, p<0.0001). Antigenemia prevalence
declined less dramatically, by 18.6%, 34.6%, 74.2%, and
54.7% in Mapou, Barrier Jeudi, Masson-Mathieu, and
Leogane, respectively (p<0.0001 in all sites except
Mapou).
Baseline mosquito infection rates 3 months before the
first MDA were 0.5%, 2.9%, 3.5%, and 4.0% in Mapou,
Masson-Mathieu, Leogane, and Barrier-Jeudi, respective-
ly. After MDA 1, infection prevalence decreased signifi-
cantly only in Masson-Mathieu (p = 0.004); however, after
2 rounds of MDA, infection was reduced significantly at
all sites (p<0.007) except Mapou (Figure 2). After MDA4,
infection prevalence was 0% during some months at all
sentinel sites, although infected mosquitoes were detected
sporadically at all sites but Mapou. The prevalence of
infective mosquitoes was lower than the prevalence of
infected mosquitoes (p<0.05), but parallel declines were
observed after MDA (data not shown).
These data were collected to monitor progress and to
provide a basis for programmatic decisions. In January
2005, 3 months after MDA 5, a meeting was convened in
Leogane with program and ministry staff to discuss the
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tion in both humans and mosquitoes demonstrated the sub-
stantial effects of the intervention through 4 MDA rounds.
However, persistent antigenemia and sporadic parasitemia
were detected at all sentinel sites. Project leaders adopted
a conservative approach and planned for MDA 6 on the
basis of the evidence of continued transmission in the sen-
tinel sites.
Several factors supported this decision, including
detection of infections in both humans and mosquitoes and
concerns about systematic noncompliance (8), the poten-
tial for inflated coverage estimates due to population
migration, the nonrepresentativeness of sentinel sites for
estimating MDA impact, and the insensitivity of blood
smears for monitoring microfilaremia. Since the cost of an
additional MDA was not prohibitive, project staff decided
that the evidence of continued transmission, the health
benefits of mass treatment to the community, and the risk
of stopping treatment prematurely justified a sixth round of
MDA in October 2005. Results from Leogane and other
programs have demonstrated that 5 rounds of MDA may
not be sufficient to interrupt transmission when baseline
antigenemia is high, whereas in low-prevalence areas <5
rounds appears to be adequate (3). Mathematical models as
well as program experience suggest that the number of
MDAs required depends on baseline intensity of infection,
assuming adequate coverage (10,11). 
Adequate monitoring data are important for making
decisions regarding continuation of mass treatment.
Microfilaremia and immunochromatographic card test
(ICT) testing are the gold standards for measuring the
impact of MDA; however, nocturnal blood collection
required for microfilaria testing is inconvenient, the high
cost of the ICT is a concern (≈$2.65), and the sensitivity of
both tests decreases as LF intensity and prevalence decline.
Entomologic monitoring provides an alternative
method of measuring the impact of MDA on transmission.
Although it circumvents the human cost of repeated blood
collection and provides a direct, real-time measure of
potential transmission, continuous mosquito collection and
dissection were more costly and labor-intensive than other
monitoring methods that we used. Conducting intermittent
rather than continuous collections may be an alternative
approach.
The limitations of these monitoring tools highlight the
need for more sensitive, standardized tools to help pro-
grams define MDA endpoints and to conduct surveillance.
Antibody responses may develop before patent infection
and serve as a cumulative measure of filarial exposure and
a proxy for transmission (12). In Egypt, antibody surveys
of children beginning school were used to monitor for inci-
dent exposure, indicative of ongoing transmission (3).
Additional studies are needed to validate antibody tests
and to analyze the relationship between antibody preva-
lence and transmission intensity.
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Figure 1. Microfilaremia prevalence determined by screening thick
blood films before and 6–9 months after annual mass drug admin-
istration in sentinel sites in Leogane Commune, Haiti. Blood sam-
ples (20 µL) were collected from 7–9 PM.
Figure 2. Prevalence of infection (microfilaremia, L1, L2, and L3)
in dissected mosquitoes collected by using gravid traps in sentinel
sites in Leogane Commune, Haiti. Data are aggregated on a
monthly basis. Dashed lines represent annual mass drug adminis-
tration intervention.In summary, MDA-based LF programs, including that
in Leogane, lead to dramatic declines in filarial infection in
humans and mosquitoes after several annual rounds of
MDA (2,3,13–15). The outcomes of the Leogane project
and others that have completed 5 rounds of MDA strongly
suggest that the duration of treatment is related to the base-
line transmission intensity and infection prevalence.
Several issues—population migration, systematic non-
compliance, and sentinel site bias—have emerged as vari-
ables that complicate decision making. Investigating their
effect on infection and transmission in an operational con-
text is critical.
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